Cellvizio® receives Wall Street Journal 2008 Technology Innovation AwardCompany has been recognized as runner-up in the Medical Device category for breaking ground and demonstrating measurable impact on the field. See the Wall Street Journal's web site for more details.
Prof. Mike Wallace interviewed on TV about his work with CellvizioProf. Mike Wallace from Mayo Clinic in Jacksonville, FL, talks about his work on characterizing colonic polyps in real time with Cellvizio. Click here to watch the interview.
Cellvizio featured on TV in LilleProf. Filoche presented his ground-breaking work with Cellvizio during prime-time news on France 3. Click here to watch the TV piece.
Cellvizio® Enables Immediate Diagnosis Of Colorectal Lesions with Malignant PotentialCellvizio® enables immediate diagnosis of colorectal lesions with malignant potential and distinguishes them from nonneoplastic polyps with high accuracy level.
Mauna Kea Technologies closes a $30 millions financing roundMauna Kea Technologies closes a $30 million financing round led by U.S.-based Psilos Group, joined by Seventure and by its shareholder CreAdev.
Three Studies Using Cellvizio® GI Featured in Major Medical JournalsCellvizio’s capabilities highlighted in november issue of clinical gastroenterology and hepatology cover page, featured article, original article and editorial. study published in gastrointestinal endoscopy demonstrates video mosaicing with Cellvizio.
Cellvizio®GI Image of the Month in Clinical Gastroenterology and HepatologyMKT is proud to report the publication of an article by Morgner et al in Clinical Gastroenterology and Hepatology.
Valérie Pécresse visits Mauna Kea TechnologiesThe French Minister of Research and Higher Education visited MKT on August 28th.
Endo-UpdateEndo-update 2013 is a two-day interventional endoscopy update course in Augsburg, Germany, with an internationally recognized faculty highlighting the latest research, skills, and technologies with simultaneous live sessions, state-of-the-art lectures, case discussions and interactive case presentations. More details to come soon !
WMIC Meeting 2013 SavannahThe World Molecular Imaging Congress is organized by the joint efforts of the “World Molecular Imaging Society – WMIS“, the “European Society for Molecular Imaging – ESMI” and the “Federation of Asian Societies for Molecular Imaging – FASMI“. The WMIC is led by the senior academic and industry professionals who have widely recognized expertise in molecular imaging. The scientific sessions held at the conference cover a broad spectrum of basic and translational sciences (pre-clinical to clinical) forming a Discovery-to-Delivery (D2D) process that helps facilitate academic and industrial partnerships. Through innovation, our goal is to optimize the D2D efforts leading to new medical and molecular imaging discoveries, greater linkages between research and market outcomes, and significant improvements in healthcare. Comme visit us and discover Cellvizio Dual Band for translational research!
CELLVIZIO DAY : TRAINING WORKSHOP AT PAOLI CALMETTES INSTITUTE - MARSEILLE, FRANCEAcquire a basic understanding of how the Cellvizio system works, and learn how to interpret Cellvizio images of the esophagus, bile duc and colon. Live cases will be observed and the latest clinical data and case studies will be analyzed.
Cellvizio News, May 2013FDA grants Mauna Kea Technologies 510(k) clearance to market AQ-Flex™19 miniprobe for fine needle aspiration procedures Mauna Kea Technologies announced that the U.S. Food and Drug Administration (FDA) has cleared the AQ‐Flex™ 19 miniprobe to provide real‐time optical biopsies during endoscopic ultrasound‐guided fine needle aspiration (EUSFNA) procedures in the digestive tract. This represents the sixth U.S. regulatory clearance for Mauna Kea Technologies’ Cellvizio on one of its dedicated miniprobes, which already obtained the CE mark in Europe.
MAUNA KEA TECHNOLOGIES ENTERS INTO MAJOR CELLVIZIO® DISTRIBUTION AGREEMENT WITH A LEADING JAPANESE MEDICAL DEVICE COMPANYPARIS, (June 13, 2013) – Mauna Kea Technologies (NYSE Euronext: MKEA, FR0010609263), leader in the optical biopsy market and developer of Cellvizio®, the fastest way to see cancer, reported that it has entered an exclusive distribution agreement in Japan with AMCO Inc. for a five-year period. This partnership further strengthens Mauna Kea Technologies’ ties with the Japanese market, and is a major step forward in the company’s efforts to obtain regulatory approval in the world’s second largest endoscopy device market after the US. The Japanese Ministry of Health, Labor, and Welfare (MHLW) requires foreign medical device companies to have a physical presence within the country or define a partnering distributor prior to approving a device for commercial sale.